OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pant on Exciting Data With PARP Inhibitors in Pancreatic Cancer

March 13th 2020

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Dr. Secord on Frontline Maintenance Therapy in Ovarian Cancer

March 13th 2020

Angeles Alvarez Secord, MD, discusses key takeaways from clinical trials that have evaluated frontline maintenance strategies in patients with advanced ovarian cancer.

Dr. Antonarakis on Updated Analysis of the KEYNOTE-199 Trial in mCRPC

March 13th 2020

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. Armaghany on Gene Sequencing in CRC

March 13th 2020

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

Dr. Westin on Potential for Chemo-Free Treatment in Large Cell Lymphoma

March 13th 2020

Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.

Dr. Raez on the Benefits of Liquid Biopsies in Newly Diagnosed Lung Cancer

March 13th 2020

Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.

Dr. Sapisochin on Determining Transplant Eligibility in HCC

March 13th 2020

Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.

Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous Carcinoma

March 13th 2020

Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.

Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC

March 13th 2020

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Dr. McKay on the Real-World Utilization of Radium-223 in mCRPC

March 13th 2020

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Dr. Chao on the Utility of MSI as a Biomarker in Gastric/GEJ Cancer

March 12th 2020

Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.

Dr. Huey on Sequencing Sorafenib Among Novel Combos in HCC

March 12th 2020

Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.

Dr. Gonzalez-Martin on the PRIMA Trial Design in Ovarian Cancer

March 12th 2020

Antonio González-Martín, MD, discusses the design of the PRIMA trial in ovarian cancer.

Dr. Choueiri on Safety Profile of MK-6482 in Advanced Clear Cell RCC

March 12th 2020

Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Dr. Coleman on Results of the VELIA Trial in Ovarian Cancer

March 12th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.

Dr. Finn on Biomarkers of Response in HCC

March 12th 2020

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Dr. Iyer on Erdafitinib-Related Hyperphosphatemia in Metastatic Urothelial Cancer

March 12th 2020

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Dr. Kaseb on the Progression of HCC Research

March 12th 2020

Ahmed O. Kaseb, MD, discusses the progression of therapy options for patients with hepatocellular carcinoma.

Dr. Oh on Design and Results of the PRINT Trial in Castration-Resistant Prostate Cancer

March 12th 2020

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Dr. Gould on the Implications of the NELSON Trial in Lung Cancer

March 11th 2020

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.